RxDoctor Payments Data

Michael Buck, MD

Family Medicine · Alexandria, LANPI 1063402667

Payments from drug & device makers

$7,089in general payments, 2019–2025

Across 425 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$754
  • Lilly USA, LLC$540
  • GSK$493
  • Pfizer$392
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$6,94098%
  • Education$300%
  • Gifts$1192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,089 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$514,573
Medicare patients
722
Services billed
14,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide214$264,533
JardianceEmpagliflozin187$184,934
FarxigaDapagliflozin Propanediol167$143,063
EliquisApixaban162$129,917
OzempicSemaglutide90$108,355
RybelsusSemaglutide59$88,636
XareltoRivaroxaban70$69,652
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$54,695
EntrestoSacubitril/Valsartan68$46,848
JanuviaSitagliptin Phosphate41$39,626
LinzessLinaclotide44$29,844
Soliqua 100-33Insulin Glargine/Lixisenatide20$21,109
Repatha SureclickEvolocumab24$20,339
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$17,497
Breo ElliptaFluticasone/Vilanterol34$17,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$540$264,533214 claims
Novo NordiskOzempic, Rybelsus$754$196,992149 claims
Boehringer IngelheimJardiance$136$184,934187 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,031$160,560190 claims
PfizerEliquis$392$129,917162 claims
GSKTrelegy Ellipta, Breo Ellipta$493$72,041105 claims
Johnson & JohnsonXarelto$212$69,65270 claims
NovartisEntresto$30$46,84868 claims
AbbVieLinzess$1,897$29,84444 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$114$21,10920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →